Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Polycythemia Vera 1Polycythemia 1Ovarian Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 35Carboplatin 35Bevacizumab 14olaparib 13niraparib 11apatinib 11Gemcitabine 10liposomal doxorubicin 9Hyperthermic Intraperitoneal Chemotherapy 9Cisplatin 9pembrolizumab 8Cyclophosphamide 8fludarabine 7Etoposide 7Topotecan 6fluzoparib 5Surveys and Questionnaires 5Drug Therapy 5Albumin-Bound Paclitaxel 5anlotinib 4Immunohistochemistry 4Ifosfamide 4Doxorubicin 4Docetaxel 4Cytoreduction Surgical Procedures 4Taxes 3Surgical Procedures, Operative 3Poly(ADP-ribose) Polymerase Inhibitors 3Neoadjuvant Therapy 3Laparoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Ovarian Neoplasms × Vorinostat × Clear all
NCT00772798 2008-10-15

A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer

Herlev Hospital

Phase 2 Unknown
70 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡